NCT04044768 2026-02-06
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
USWM, LLC (dba US WorldMeds)
National Cancer Institute (NCI)
GlaxoSmithKline
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.